September 21, 2018
The number of people with Alzheimer’s disease will nearly triple over the next 40 years, unless something dramatic happens to change trends, the Centers for Disease Control and Prevention said this week.
Right now, about 5 million people have Alzheimer’s, the CDC says. That’s about 1.6 percent of the population. But by 2060, that number will hit nearly 14 million, which will then be 3.3 percent of the projected population.
September 11, 2018
Mass General Research Institute Blog (August 28, 2018): Event Highlights Progress on Brain Disease Research
Determined collaboration and groundbreaking technology have led to exciting advances in efforts to solve the challenges of brain diseases, researchers from the MassGeneral Institute for Neurodegenerative Diseases(MIND) told patients, families and friends recently.
September 6, 2018
A study by a Massachusetts General Hospital (MGH) research team finds that neurogenesis — inducing the production of new neurons — in the brain structure in which memories are encoded can improve cognitive function in a mouse model of Alzheimer’s disease. Their investigation shows that cognition can be blocked by the hostile inflammatory environment in the brains of patients with Alzheimer’s disease and that physical exercise can “clean up” that environment, allowing new nerve cells to survive and thrive and improving cognition in the Alzheimer’s mice.
September 6, 2018
A multi-institutional study led by Harvard Medical School investigators based at Massachusetts General Hospital and researchers from Johns Hopkins University School of Medicine has found how the abnormal form of tau, which accumulates in the neurofibrillary tangles that characterize Alzheimer’s disease, can disrupt the normal function of brain cells.
August 30, 2018
Science Magazine (August 30, 2018): The Alzheimer’s Gamble: NIH Tries to Turn Billions in New Funding into Treatment for Deadly Brain Disease
When molecular biologist Darren Baker was winding up his postdoc studying cancer and aging a few years ago at the Mayo Clinic in Rochester, Minnesota, he faced dispiritingly low odds of winning a National Cancer Institute grant to launch his own lab. A seemingly unlikely area, however, beckoned: Alzheimer's disease. The U.S. government had begun to ramp up research spending on the neurodegenerative condition, which is the sixth-leading cause of death in the United States and will afflict an estimated 14 million people in this country by 2050.
August 22, 2018
“We’re lost,” said Truus Ooms, 81, to her friend Annie Arendsen, 83, as they rode a city bus together.
“As the driver, you should really know where we are,” Ms. Arendsen told Rudi ten Brink, 63, who sat at the wheel of the bus.
But she was joking.
August 16, 2018
Rhiana Kohl has faced many sad surprises in the seven years since her husband, Alfredo Bartolozzi, first showed symptoms of Alzheimer’s disease. But perhaps the biggest shock was finding out that even health care workers often don’t understand this common illness.
During a hospital stay, an X-ray technician didn’t grasp that Bartolozzi couldn’t follow directions. In an emergency room visit, staffers asked factual questions of a stricken man who didn’t know where he was.
August 1, 2018
Building on their development of the first culture system to replicate fully the pathology behind Alzheimer’s disease, a Massachusetts General Hospital (MGH) research team has now produced a system that includes neuroinflammation, the key biological response that leads to the death of brain cells. The investigators describe their system, which incorporates the glial cells that that not only surround and support neurons but also provide some immune system functions, in a paper published in Nature Neuroscience.
July 30, 2018
CNN News (July 30, 2018): Borrowing from the Cancer Playbook to Find Treatment for Alzheimer's Disease
It's been notoriously difficult to develop medicines for Alzheimer's disease, the sixth leading cause of death in the United States. Each year, it seems, pharmaceutical companies release data from studies of promising drug candidates that merit only a collective sigh of disappointment.
In search of fresh ideas, researchers have begun to borrow a phrase or two from the more familiar language of cancer treatment.
July 26, 2018
An exciting update on the race to end Alzheimer's disease: in a clinical trial, a new drug reduced amyloid plaques and improved cognitive function -- the first time a drug has had both effects. Dr. Reisa Sperling of the MADRC, quoted in the The New York Times, said, "I don't know if we've hit a home run yet. It's important not to over-conclude on the data. But as a proof of concept, I feel like this is very encouraging." To read the article in its entirety, click here.